Eltrombopag/Revolade

DRUG2 trials

Sponsors

Associazione Qol-one

Conditions

Myelodysplastic SyndromesThrombocytopenia

Phase 2

Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes

Active, not recruitingNCT02912208

Associazione Qol-oneMyelodysplastic Syndromes, Thrombocytopenia

Start: 2011-06-11End: 2026-10-31Target: 174Updated: 2022-01-28

Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q

TerminatedNCT02928419

Associazione Qol-oneMyelodysplastic Syndromes

Start: 2015-05-31End: 2018-09-30Updated: 2018-09-25

Related Papers

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Journal of Clinical Oncology2023-06-0929 citations

Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study

Acta Haematologica2023-01-012 citations